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between human clusterin and the Alzheimer's disease-associated amyloid-β 1-40 peptide (Aβ 1-40), which
is prone to aggregate into an ensemble of oligomeric intermediates implicated in both the proliferation of
amyloid fibrils and in neuronal toxicity. Using highly sensitive single-molecule fluorescence methods, we
have found that Aβ 1-40 forms a heterogeneous distribution of small oligomers (from dimers to 50-mers),
all of which interact with clusterin to form long-lived, stable complexes. Consequently, clusterin is able to
influence both the aggregation and disaggregation of Aβ 1-40 by sequestration of the Aβ oligomers.
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ABSTRACT
In recent genome-wide association studies, the extracellular chaperone protein, clusterin, has
been identified as a newly-discovered risk factor in Alzheimer’s disease. We have examined the
interactions between human clusterin and the Alzheimer’s disease-associated amyloid-β140
peptide (Aβ140) which is prone to aggregate into an ensemble of oligomeric intermediates
implicated in both the proliferation of amyloid fibrils and in neuronal toxicity. Using highly
sensitive single molecule fluorescence methods, we have found that Aβ140 forms a
heterogeneous distribution of small oligomers (from dimers to 50mers), all of which interact with
clusterin to form long-lived, stable complexes. Consequently, clusterin is able to influence
strongly both the aggregation and disaggregation of Aβ140 by sequestration of the Aβ oligomers.
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These results not only elucidate the protective role of clusterin but also provide a molecular basis
for the genetic link between clusterin and Alzheimer’s disease.

INTRODUCTION
The aggregation of amyloidogenic peptides and proteins is a highly heterogeneous
process as monomers aggregate in a stepwise manner via a series of oligomeric intermediates to
form β-sheet-rich fibrillar structures1,2. These oligomers have been implicated not only in the
further generation of aggregates but also in the neurotoxicity associated with many
neurodegenerative diseases1,37. The detection and characterization of the various oligomeric
intermediates and their interactions with other proteins has proved to be a difficult task for
ensemble-level techniques as a result of the inherent heterogeneity of the species involved.
Recently, however, a variety of techniques has been developed to detect and characterize
molecular interactions at the level of single molecules812. We have applied two forms of such
techniques to investigate the aggregation and fibril disaggregation processes of the Alzheimer’s
disease (AD)-associated peptide, amyloid-β140 (Aβ140) and its interactions with clusterin, an
extracellular chaperone protein which has been found to be colocalized with senile amyloid
plaques and has recently been genetically associated with AD1316.
The single molecule techniques that we have utilized are able to detect and characterize
the ensemble of oligomeric species formed during the self-assembly and disassembly processes
of Aβ140 and have been implicated in the toxicity associated with AD1,5,6,17. The first of these
techniques, confocal two color coincidence detection (cTCCD), uses two spatially overlapped
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Gaussian laser beams that are combined to create a single confocal volume. cTCCD identifies
multimolecular species bearing two different types of fluorophores through the observation of
coincident bursts of fluorescence when they pass through this confocal volume, thus enabling
oligomeric species to be detected and analyzed8,10. The number of peptide molecules present in
each oligomer, denoted the oligomer size, can be measured by comparing the fluorescence
brightness values of the coincident fluorescence bursts to the brightness values of non-coincident
(monomeric) bursts. This method is based on the principle that oligomers contain a greater
number of molecules, and hence fluorophores, than monomers and therefore will emit
proportionally brighter bursts. In this work, we refer to this metric as the “apparent size” of an
oligomer since this parameter is determined indirectly from the fluorescence intensity of the
species (see Methods, Supplementary Methods and Supplementary Figs. 13 for details).
The second technique is a two-color version of total internal reflection fluorescence
microscopy (TIRFM), an imaging technique that uses two overlapped lasers of different
wavelengths to create dual excitation within the imaging field. Species bearing different
fluorophores deposited onto a surface within this field can be imaged, and the distribution of
colocalization of fluorescence can be analyzed to give images with detailed information about
the composition, size and morphology of the species present. (See Methods, Supplementary Fig.
1, and Supplementary Methods for details of data acquisition and instrumentation).
In this study, we have combined solution-phase detection by cTCCD with imaging of
surface-bound species by TIRFM in order to gain insight not only into the aggregation process of
Aβ140 but also into the interactions between the AD-linked extracellular chaperone, clusterin,
and the various species populated along the Aβ140 aggregation pathway.
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RESULTS
Characterizing the aggregation of Aβ140
We first used cTCCD to characterize the species formed during the process of Aβ140
aggregation and disaggregation in the absence of clusterin. To study the aggregation process,
equimolar quantities of the Aβ140 peptide, labeled with either the HiLyteFluor488 fluorophore
or the HiLyteFluor647 fluorophore (Anaspec), were mixed and the sample was incubated at pH
7.4 and 37

C. cTCCD measurements were then made every 2 to 3 h as the peptides aggregated

and eventually formed amyloid fibrils (Fig. 1a). A series of control experiments revealed that the
presence of neither fluorophore had any appreciable effect on the bulk aggregation behavior of
Aβ140, a result in accord with other studies using the same fluorescent peptides1821
(Supplementary Fig. 2). Analysis of the distribution of oligomers reveals a variety of soluble
species, the majority of which are stable for over three hours at the concentrations and
temperature required for cTCCD characterization (~2550 pM, 21 C). In addition, control
experiments demonstrated that the technique is capable of detecting even small quantities of
aggregates and that the species present after dilution to picomolar sample concentrations are
highly representative of those present at the higher concentrations under which aggregation
readily takes place (600 nM – 2 µM) (see Supplementary Dicussion and Supplementary Fig.
3a,b).
We first carried out aggregation experiments at a concentration of Aβ140 of 30 nM, a
value similar to its typical physiological concentration in cerebrospinal fluid (CSF)22. We
observed the formation of 300 pM of oligomers representing approximately 1% of the total
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number of molecules present. This result confirms previous speculation that oligomeric species
can form at Aβ140 concentrations similar to those in physiological environments but at which
fibril formation can be very slow23. In order to be able to collect data under concentrations where
aggregation occurs more rapidly and it where it is possible to conduct bulk experiments and
single molecule measurements with high signal-to-noise ratios, the concentrations were
increased either to 600 nM or to 2 µM for further experiments; these experimental conditions
were also selected as they yielded highly reproducible data. The aggregation experiments at these
higher concentrations reveal a rise in the population of stable oligomeric species to a peak
concentration of ~20 nM during the incubation of 2 μM Aβ140 (again representing about 1% of
the total molecules present) along with a 75% decrease in the monomer concentration during the
growth phase of fibril formation (Fig. 1a).
The relative quantities of the different oligomeric forms that could be observed decreased
exponentially with increasing apparent size under all conditions examined in this study (dimers
were most abundant; the probability of finding a 10-mer relative to a dimer is ~3000:1). Indeed,
this distribution of apparent sizes was sustained throughout the progress of the aggregation
reaction suggesting that many intermediate species are involved in the growth of amyloid fibrils
(Fig. 1b, Supplementary Fig. 3ce). At these higher concentrations we observe that the
distribution of stable oligomer sizes is effectively the same as that formed at a concentration of
30 nM (Fig. 1c). This exponential form of the distribution of apparent oligomer sizes directly
observed in our experiments has been predicted by theoretical analysis of the aggregation of
other protein systems, and is consistent with models of both the bulk kinetics and the molecular
processes of amyloid growth7,24.
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Characterizing the disaggregation of Aβ140 fibrils
We then set out to study the species present during the process that is the reverse of
aggregation into fibrils, their disaggregation. Aβ140 fibrils were formed from monomeric
peptides at a concentration of 8 µM, pelleted by centrifugation, washed, and finally re-suspended
in buffer in the absence of any additional Aβ140. Using TCCD, we monitored the release of
soluble species into the buffer from the fibrils at a rate of (9.3  3.1) ×105 s1 (n=12, s.e.m.)
(Fig. 1d, see Supplementary Methods for details).

These results are similar to previous

observations of exchange between amyloid fibrils and soluble proteins25,26. However, the single
molecule experiments in the present study additionally reveal that the species released include a
small population of stable oligomers as well as monomeric species (Fig. 1c).
After 50 h of disaggregation the concentrations of the various species in solution were
constant and we could assume that the system had reached equilibrium. We then derived the
thermodynamic stabilities of the various species present. The values of ΔGº are 18.2  0.5 kJ
mol1 for dimers and an average of38.9  2.7 kJ mol1 for the larger oligomers (error values are
s.d.). These values are in good agreement with previous bulk measurements of the free energy of
the formation of amyloid fibrils (36 kJ mol1)27.

They also indicate that the dimers are

inherently less thermodynamically stable than all larger oligomers, and that the stability of the
larger oligomers is largely independent of their size (Table 1), findings that are consistent with
previous computational analyses28.

Effect of clusterin on the aggregation of Aβ140
6

The observation of stable distributions of oligomers by cTCCD during the aggregation
and disaggregation processes of Aβ140 provided a framework for the investigation of interaction
of clusterin and such ensembles of species. In a series of experiments, we first used unlabeled
clusterin to explore any changes in the Aβ140 oligomer distribution resulting from the presence
of the chaperone and then AlexaFluor647-labeled clusterin to characterize the specific
interactions between clusterin molecules and Aβ140 species. Control experiments confirmed that
AlexaFluor647-labeled clusterin behaved in a similar manner to its unlabeled counterpart which
indicates that fluorescent labeling had no marked effect on the properties of clusterin studied in
this work (Supplementary Fig. 4a).
Addition of equimolar quantities of clusterin to monomeric Aβ140 prior to the start of the
aggregation reaction dramatically inhibits the appearance of small oligomeric species, a finding
that is consistent with bulk measurements showing that clusterin substantially inhibited fibril
formation (Fig. 2a)29,30. Moreover, when we added clusterin to solutions in which aggregation
had progressed to a stage where a significant population of oligomers is present, further selfassociation of the peptides was halted (Fig. 2b). At various points throughout the aggregation
reaction, the fraction of Aβ1-40 peptides that formed oligomers in the absence of clusterin
matched well with the fraction of Aβ1-40, at these same points, that formed complexes with
clusterin when it was added to these oligomeric solutions (Fig. 2c). This result indicates that
clusterin:Aβ complexes are very long-lived, persisting for over 50 h following dilution to
nanomolar concentrations (Fig. 2d). The binding between clusterin and Aβ oligomers was
observed not only at concentrations of 2 µM but also at concentrations of 100 nM, conditions
under which fibrils are not observed to form for days. The clusterin:Aβ complexes formed at
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these low concentrations were found to persist, after dilution, at picomolar concentrations for
over 200 h (Supplementary Fig. 4bd). Furthermore, the distribution of the sizes of the Aβ140
oligomers observed in our experiments was not substantially altered in the presence of clusterin
(Fig. 3a, Supplementary Fig. 4c). We therefore conclude that the growth of larger aggregates,
and ultimately amyloid fibrils, is inhibited as a result of the very effective sequestration of Aβ
oligomers by clusterin molecules.

Effect of clusterin on the disaggregation of Aβ140 fibrils
Studies of Aβ140 fibril disaggregation in the presence of clusterin reveal that oligomers
released from the fibrils bind to clusterin molecules resulting in an increase in the total oligomer
population compared to that observed in the absence of clusterin (Fig. 3b). Our observation of a
population of oligomers resulting from fibril disaggregation is consistent with the oligomeric
‘halos’ found around Aβ plaques in a mouse model of Alzheimer’s disease31. This result is also
in line with studies suggesting clusterin increases the observable oligomer population, perhaps
because of stabilization of Aβ oligomers by clusterin32. As found under aggregation conditions,
the complexes between clusterin and the Aβ oligomers observed during disaggregation are very
long-lived, persisting at nanomolar concentrations for over 50 h (Fig. 2d). In each of these
complexes, the ratio of clusterin:Aβ had a median value of 1.2  1.1 (interquartile range)
suggesting that there is a direct correlation between the number of clusterin molecules and the
number of Aβ peptides in a complex (Supplementary Fig. 5). In addition, the presence of
clusterin bound to the Aβ fibrils is found to decrease both the rate and the extent of fibril
disaggregation by inhibiting dissociation into monomers (the rate changes to (17  2.7) × 106
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s1, n=8, s.e.m. with clusterin from (9.3  3.1) × 105 s1, n=12, s.e.m. without clusterin) (Fig.
3b,c, Supplementary Fig. 6). Similar binding of chaperones to fibrils and inhibition of their
disaggregation has been previously observed in experiments with other systems3335. The relative
change in monomer and oligomer populations was reflected in an increase in the magnitude of
the free energies of formation of dimers (from 18.2  0.5 to 25.8  2.6 kJ mol1, both s.d.) and
of larger oligomers (from 38.9  2.7 to 43.9  1.0 kJ mol1 both s.d.) when clusterin is present
(Table 1). In all aggregation and disaggregation experiments, regardless of the presence or
absence of clusterin, the distribution of oligomeric species followed an approximately
exponential decrease with increasing apparent size (Fig. 3a).

DISCUSSION
The present studies reveal that under the experimental conditions used in this work,
clusterin binds and sequesters oligomers formed during both the aggregation of Aβ140
monomers and the disaggregation processes of Aβ140 fibrils thereby inhibiting the further
growth or dissociation of these oligomers. In the CSF, where aggregation is likely to be of
particular significance, clusterin is present at concentrations between 20 and 60 nM36, levels in
excess of those of Aβ1

40

present between 1 and 10 nM22, a concentration regime in which stable

oligomers of Aβ1−40 can be formed, according to our data. Clusterin is, therefore, present under
normal conditions at levels appropriate for prevention of the formation or growth of oligomers
and their consequent toxicity29. Additionally, the persistence times measured here for complexes
between clusterin and Aβ140 oligomers (from 50 h to greater than 200 h) are long enough to
allow for crucial in vivo processes such as Aβ140 production (~15 h), Aβ140 clearance (~14 h),
9

and astrocytic endocytosis (between 12-24 h)37-39. This is particularly noteworthy considering
that previous studies have correlated binding of Aβ species by clusterin to the in vivo degradation
of the peptides29,40,41.
Our single molecule experiments show that the extracellular chaperone clusterin binds to
all members of the ensemble of soluble oligomers found to be present during the aggregation and
disaggregation of Aβ140 in our experiments. In this way, clusterin is able to prevent further
growth and proliferation of aggregated species and in vivo, is likely to sequester the potentially
toxic oligomeric species until they can be processed and degraded38,41,42. The methodology
described in this study that has enabled these data to be obtained should be readily applicable to
different aggregation conditions and to a wide range of disease-associated peptides and proteins
and therefore represents a powerful means of probing, at the level of individual molecules, the
seminal link between protein misfolding, aggregation and disease1.
In the particular case of the Aβ peptide discussed in this work, the ability of clusterin to
sequester misfolded and potentially toxic oligomers provides a molecular basis for the recently
identified genetic association between clusterin and Alzheimer’s disease13,14.

Indeed, any

perturbations that result in reduced clusterin levels, or in a reduction of clusterin’s ability to form
stable and long-lived complexes with Aβ oligomers, are likely to increase susceptibility to
Alzheimer’s disease13,14.
Supplementary Information is linked to the online version of the paper.
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Table 1. Kinetic and Thermodynamic Parameters
Parameter

Without clusterin (n)

With clusterin (n)

Rate of monomer and oligomer release (s1)

(9.3  3.1)×105 (12)

270  20 (12)
0.16  0.06 (12)


(1.7  0.3)×105
(8)
(9.8  0.9)×107
(3)
120  20 (8)
0.42  0.1 (8)
90  14 (3)

23.0  2.9 (4)
39.3  3.0 (11)




18.2  0.5 (3)
38.9  2.7 (12)
43.8  24.5 (3)
29.1  0.3 (12)
80.8  83.5 (3)
28.3  1.1 (12)

25.8  2.6 (4)
43.9  1.0 (12)





Rate of clusterin release (s1)
Final concentration of all species (nM)
Final concentration of oligomeric species (nM)
Final soluble clusterin concentration (nM)



Aggregation
ΔG (dimer) (kJ mol1)
ΔG (larger oligomer) (kJ mol1)
Disaggregation
ΔG (dimer) (kJ mol1)
ΔG (larger oligomer) (kJ mol1)
ΔH (dimer) (kJ mol1)
ΔH (larger oligomer) (kJ mol1)
ΔS dimer (kJ mol1)
ΔS larger than dimer (kJ mol1)

The rates were derived from fitting monomolecular dissociation functions to the plots of species
released as a function of time from disaggregation experiments. All thermodynamic values—free
energies (ΔG), enthalpies (ΔH), and entropies (ΔS) of formation for various sizes of
oligomers—were determined from the steady state apparent size distributions of the various
species. Errors for rate values are s.e.m. and errors for thermodynamic values are s.d.
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FIGURE LEGENDS

Figure 1 Bulk and single molecule studies of Aβ140. (a) Appearance and disappearance of
species populated during the aggregation of Aβ140 (2 µM at 37 C with agitation). Fibril
formation monitored by thioflavin T (ThT) fluorescence (top). The inset (top) is a transmission
electron microscopy (TEM) image of the fibrils present after 24 h of incubation (scale bar is 200
nm). Concentration of soluble oligomers (dimers50mers) (middle), and concentration of
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monomeric species (bottom) are both tracked using cTCCD. The data are averaged from
multiple experimental repetitions (2 μM Aβ140, n=3, error bars are s.e.m.). (b) A representative
distribution of apparent sizes of oligomers formed during Aβ140 aggregation and disaggregation
(error bars are s.d.). Insets are zoomed into regions of dimers15-mers and 16-mers50-mers to
provide greater detail. (c) A comparison of the distributions of apparent oligomer sizes during
aggregation and disaggregation experiments (2 μM Aβ140 aggregation, n=3; disaggregation,
n=12; 1030 nM Aβ140 aggregation, n=4; error bars are s.e.m.). (d) Time dependence of the
concentration of soluble species released from a pellet of fibrils (n=12, error bars are s.e.m.).
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Figure 2 The effects of clusterin on the aggregation
of Aβ140. (a) Fraction of oligomers detected in
solution during the aggregation of Aβ140 with and
without clusterin (Aβ140 and clusterin are both at a
concentration of 600 nM, n=3, error bars are s.e.m.).
(b) TIRFM image of the species present after 24 h of
aggregation of a 2 μM solution of Aβ140 without
clusterin (left). TIRFM image of a 2 μM solution of
Aβ140 after 24 h of aggregation but with 2 µM
clusterin added 4 h after the start of the reaction,
during the fibril growth phase (right).

An

approximately 50% reduction in the average size of
species present is observed in the presence of
clusterin (from 1400  200 nm without clusterin to
780  60 nm with clusterin, s.e.m., P-value is 0.01,
two-sample independent, two-tailed, t-test). Scale
bars are 5 µm. (c) Fractions of species formed during
the aggregation of a 2 μM solution that are
oligomeric and that are in Aβclusterin complexes.
(n=3, error bars are s.e.m.). (d) Proportion of
Aβclusterin complexes persisting at 1020 nM (total
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peptide concentration) at 21 C. Complexes were formed between clusterin and oligomers from
both aggregation and disaggregation reactions. For both traces, n=3, error bars are s.e.m. There
is no statistically significant change in the proportion of complexes with oligomers formed
during either the disaggregation experiment (P-value of 0.77, ANOVA single-factor) or the
aggregation experiment (P-value of 0.99, ANOVA single-factor).
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Figure 3 The effects of clusterin on the
disaggregation

of

fibrils.

Aβ140

(a)

Distributions of apparent sizes of oligomers
formed

during

aggregation

and

disaggregation reactions with and without
clusterin. (Aggregation without clusterin,
n=2, error bars are range; aggregation with
clusterin,

n=3;

clusterin,

n=10;

disaggregation

without

disaggregation

with

clusterin, n=3; error bars are s.e.m.). (b)
Time dependence of the release of soluble
species

during

the

disaggregation

experiments in the presence and absence of
clusterin

(top),

increased

oligomer

concentration in the presence of clusterin in
the

concentration

plateau

region

(significant with a P-value of 0.002)
(bottom left) and decreased monomer
concentration in the presence of clusterin,
in

the

concentration

plateau

region

(significant with a P-value of 0.0003)
(bottom right). Both correlations were
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analyzed using a two-sample independent, two tailed t-test, n=8, and error bars are s.e.m. (c)
TIRFM imaging of HiLyte488Fluor-labeled Aβ140 fibrils incubated overnight at room
temperature with AlexaFluor647-labeled clusterin. Aβ140 fluorescence only (left), clusterin
fluorescence only (middle), and colocalization of the two species (right). Scale bars are 5 μm.

ONLINE METHODS
cTCCD instrumentation
The instrumentation used in this study has been described previously10. Gaussian laser beams of
two colors (a tuned diode laser emitting at 488 nm (Spectra Physics, Cyan CDRH) and a heliumneon laser emitting at 633 nm (Melles Griot, 25LHP151) were overlapped and directed into a
confocal microscope (Nikon Eclipse TE2000-U) to achieve dual-excitation in the confocal
volume. The beams then pass through an oil-immersion objective (Appochromat 60x, NA 1.40,
Nikon) and into the sample with a final beam diameter of approximately 260 nm. The laser
powers used were 60  5 μW for the 633 nm laser and 50  5 μW for the 488 nm laser and are
low enough that photobleaching of the fluorophores during their time in the probe volume was
not appreciable8. During measurements, 200 μL of sample was placed on a 1x1 cm area of a
BSA-coated glass coverslip (VWR, 631-1339). Then the beam was focused on a confocal plane
that is 10 μm into the measurement solution, above the coverslip surface.
The fluorescence photons emitted from the sample were collected through the objective, passed
through a 50 μm pinhole (Melles Griot), separated into the two different detection channels
(dichroic 585DRLP Omega Filters), and directed to separate avalanche photodiode detectors
(APDs) (SPCM-AQR-14, Perkin-Elmer Optoelectronics). The APDs feed photon count data in 1
ms bins into multichannel scalar cards on a personal computer (MCS-PCS, Ortec) which were
saved for analysis in 600800, 8000 ms frame units. During each measurement, the microscope
stage was scanned using two orthogonal DC motors (M-112.1DG, Physik
Instrumente, Karlsruhe, Germany) across the confocal volume at a constant rate of 200 µm s1.
See Supplementary Methods for further instrumentation details.
TIRFM instrumentation
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Imaging was performed using total internal reflection fluorescence microscopy (TIRFM) which
aligns the outputs from a HeNe laser operating at 633 nm (25LHP991230, Melles Griot) and a
diode laser operating at 488 nm (PC13589, Spectra Physics) and directs them down the edge of a
TIRF objective (60x Plan Apo TIRF, NA 1.45, Nikon) mounted on a Nikon TE200 microscope.
Fluorescence collected by the same objective was separated from the returning TIR beam by a
dichroic (FF500646, Laser2000), split into blue and red components (585 DXLR, Omega
Optical) and filtered using Dual-View (Optical Insights) mounted filters. The images were
simultaneously recorded on an EMCCD (Cascade II: 512 Princeton instruments,) whereby the
EMCCD was split so that each color was recorded on one half of the EMCCD, operating at 70
C. Data were acquired 7.9 frames s-1 using Metamorph software (Molecular Devices). See
Supplementary Methods for further instrumentation details.
Aβ peptide preparation
Monomeric solutions of HiLyteFluor488 and HiLyteFluor647-labeled Aβ140 (Anaspec) were
prepared by dissolving the lyophilized peptide in pH 12 NaOH followed by sonication over ice
for 30 min (Bandelin Sonorex) and subsequent flash freezing into aliquots43. Prior to each of the
incubations, aliquots of each peptide were brought to pH 7.4 by diluting into SSPE buffer (150
mM NaCl, 10 mM Na2H2PO4 x H2O, 10 mM Na2EDTA, pH 7.4) to the desired aggregation
reaction concentration and placed under relevant conditions (e.g. 37 C, agitation). The
concentration for each labeled peptide was measured before mixing using cTCCD.
Preparation and labeling of clusterin
Clusterin was extracted from human serum from Wollongong Hospital (Wollongong, NSW,
Australia), as described previously44 and labeled using the AlexaFluor647 dye with a
succinimide linker (Invitrogen). See Supplementary Methods for details.
cTCCD and TIRFM data acquisition
For the aggregation experiments, Aβ140 (30 nM to 2 μM) was incubated in SSPE buffer (defined
above) at 37 C with agitation (200 rpm on a rotary shaker). Samples were taken every 23 hours
and analyzed using cTCCD. For experiments with clusterin, the chaperone was added at a 1:1
molar ratio.
For disaggregation experiments Aβ140 fibrils were first prepared by a static incubation of an 8
μM solution of Aβ140 for 72 h at 37 C. Pelleting and washing were carried out by centrifugation
at ~10,000×g for 30 min followed by two identical washing steps involving re-suspension of the
pellet in SSPE buffer and additional centrifugation at ~10,000×g for 2 min; finally the pellet was
re-suspended in SSPE buffer. The soluble species in the solution were monitored and analyzed
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using cTCCD. For experiments with chaperones, clusterin and Aβ fibrils were incubated together
for 1216 h at 21 C and any clusterin that was not bound to fibrils was removed via
centrifugation (leaving 100200 nM clusterin bound to fibrils).
See Supplementary Methods for details.
Quantification of oligomer distributions
The extent of oligomerization of a given sample was tracked by separating bursts coincident in
both blue and red detection channels from non-coincident bursts. Quantification of oligomer
distributions for cTCCD measurements was performed by analyzing the brightness of the
coincident, oligomeric bursts. The brightness in the blue (488 nm) detection channel was
corrected to account for changes in emission due to FRET between the HiLyteFluor488-labeled
and HiLyteFluor647-labeled peptides within an oligomer (see Supplementary Methods for
details). Then the FRET corrected blue channel brightness was scaled by the average burst
brightness for a blue monomer to yield an average number of blue Aβ molecules in each
oligomer. These data were then scaled by a factor of two to account for the fact that the bluelabeled peptides made up only half of the molecules in the aggregating solutions, to find the
apparent size. Uncertainties in the measurement of this quantity arise from factors that include
the Gaussian nature of the probe-volume illumination, corrections for the error associated with
assuming oligomers have equal numbers of red and blue peptides, as well as the inherent
variation in the number of photons emitted by a single fluorophore. Both Aβ oligomers and
clusterin-Aβ complexes were treated similarly with respect to the effects of FRET.
Statistical analysis
Statistical tests were performed to determine the significance of changes in distributions of the
apparent sizes of oligomers as well as the persistence of oligomeric species. In order to compare
two values, two-sample, two-tailed, independent t-tests were used. For comparison of multiple
values, ANOVA one-factor tests were used.
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